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meBACKGROUND Inﬂammation drives atherosclerotic plaque rupture. Although inﬂammation can be measured using
ﬂuorine-18-labeled ﬂuorodeoxyglucose positron emission tomography ([18F]FDG PET), [18F]FDG lacks cell speciﬁcity,
and coronary imaging is unreliable because of myocardial spillover.
OBJECTIVES This study tested the efﬁcacy of gallium-68-labeled DOTATATE (68Ga-DOTATATE), a somatostatin
receptor subtype-2 (SST2)-binding PET tracer, for imaging atherosclerotic inﬂammation.
METHODS We conﬁrmed 68Ga-DOTATATE binding in macrophages and excised carotid plaques. 68Ga-DOTATATE PET
imaging was compared to [18F]FDG PET imaging in 42 patients with atherosclerosis.
RESULTS Target SSTR2 gene expression occurred exclusively in “proinﬂammatory” M1 macrophages, speciﬁc
68Ga-DOTATATE ligand binding to SST2 receptors occurred in CD68-positive macrophage-rich carotid plaque regions, and
carotid SSTR2 mRNA was highly correlated with in vivo 68Ga-DOTATATE PET signals (r ¼ 0.89; 95% conﬁdence interval
[CI]: 0.28 to 0.99; p ¼ 0.02). 68Ga-DOTATATE mean of maximum tissue-to-blood ratios (mTBRmax) correctly identiﬁed
culprit versus nonculprit arteries in patients with acute coronary syndrome (median difference: 0.69; interquartile
range [IQR]: 0.22 to 1.15; p ¼ 0.008) and transient ischemic attack/stroke (median difference: 0.13; IQR: 0.07 to 0.32;
p ¼ 0.003). 68Ga-DOTATATE mTBRmax predicted high-risk coronary computed tomography features (receiver operating
characteristics area under the curve [ROC AUC]: 0.86; 95% CI: 0.80 to 0.92; p < 0.0001), and correlated with
Framingham risk score (r ¼ 0.53; 95% CI: 0.32 to 0.69; p <0.0001) and [18F]FDG uptake (r¼ 0.73; 95% CI: 0.64 to 0.81;
p < 0.0001). [18F]FDG mTBRmax differentiated culprit from nonculprit carotid lesions (median difference: 0.12; IQR: 0.0
to 0.23; p ¼ 0.008) and high-risk from lower-risk coronary arteries (ROC AUC: 0.76; 95% CI: 0.62 to 0.91; p ¼ 0.002);
however, myocardial [18F]FDG spillover rendered coronary [18F]FDG scans uninterpretable in 27 patients (64%). Coronary
68Ga-DOTATATE PET scans were readable in all patients.
CONCLUSIONS We validated 68Ga-DOTATATE PET as a novel marker of atherosclerotic inﬂammation and conﬁrmed
that 68Ga-DOTATATE offers superior coronary imaging, excellent macrophage speciﬁcity, and better power to discrim-
inate high-risk versus low-risk coronary lesions than [18F]FDG. (Vascular Inﬂammation Imaging Using Somatostatin
Receptor Positron Emission Tomography [VISION]; NCT02021188) (J Am Coll Cardiol 2017;69:1774–91) © 2017 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).m the aDivision of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom; bHeart Center, Rig-
ospitalet, Copenhagen, Denmark; cDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, United
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
BMI = body mass index
CT = computed tomography
CVD = cardiovascular disease
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1775S ystemic inﬂammation triggers culprit patho-genic mechanisms, relating clinical cardio-vascular disease (CVD) risk factors to
atherosclerotic plaque progression and rupture (1).
Quantifying vascular inﬂammation in atheroscle-
rosis may reveal mechanistic pathways, allow efﬁ-
cacy testing of new drugs, and improve CVD risk
prediction.SEE PAGE 1792
ECG = electrocardiogram
FDG = ﬂuorodeoxyglucose
ICC = intra-class coefﬁcient
PET = positron emission
tomography
SST2 = somatostatin receptor
subtype-2
TBR = tissue-to-blood ratio
TBRmax = maximum tissue-to-
blood ratios
TIA = transient ischemic attackCarotid, aortic, and peripheral arterial inﬂamma-
tion can be measured by ﬂuorine-18-labeled ﬂuo-
rodeoxyglucose positron emission tomography/
computed tomography ([18F]FDG PET/CT) (2). How-
ever, myocardial [18F]FDG signal spillover occurs due
to myocardial muscle [18F]FDG uptake, often
hampering coronary artery signal quantiﬁcation (3).
Lack of cell speciﬁcity and the inﬂuence of
hypoxia on [18F]FDG uptake within macrophages and
other cells (4) are further limitations of [18F]FDG
imaging.
Up-regulation of the G-protein-coupled receptor
somatostatin receptor subtype-2 (SST2) occurs on the
surface of activated macrophages (5). Pre-clinical
(6,7) and retrospective (8-10) studies suggest that
gallium-68-labeled [1,4,7,10-tetraazacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid]-D-Phe1, Tyr3-octreotate
(DOTATATE), a PET ligand with high-speciﬁcity
binding afﬁnity for SST2 (11), may be superior to
[18F]FDG in marking macrophage activity, particu-
larly in the coronary arteries. However, robust eval-
uation of 68Ga-DOTATATE in atherosclerosis is
lacking.
We present a prospective clinical study evaluating
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RNA SEQUENCING. To determine target
speciﬁcity of 68Ga-DOTATATE imaging in
atherosclerosis, expression of the SSTR1–5
genes within in vitro- differentiated macro-
phage subtypes and other blood-derived
cells relevant to atherosclerosis were char-
acterized using population-based “next
generation” RNA sequencing data from the
European BLUEPRINT (a BLUEPRINT of
haematopoietic epigenomes) project, for
which all data are publicly available (12). The
expression levels of glucose transporter 1
(GLUT1) and glucose transporter 3 (GLUT3)
genes were also analyzed from the dataset;
these genes encode the main glucose trans-
porters that facilitate uptake of [18F]FDG in
atherosclerotic plaques.CLINICAL STUDY. In the VISION (Vascular Inﬂam-
mation imaging using Somatostatin receptor positron
emissION tomography; NCT02021188) study, an un-
selected “real-world” cohort of patients with wide-
ranging severity of stable (n ¼ 18) and unstable (n ¼
24) CVD was prospectively enrolled from Adden-
brooke’s Hospital, Cambridge, United Kingdom
(Figure 1). “Stable” patients had stable angina or
asymptomatic atherosclerosis and at least a 30% ste-
nosis of a major epicardial coronary artery or an in-
ternal carotid artery. “Unstable” patients had
experienced a clinical event (acute coronary syn-
drome [ACS] or carotid territory transient ischemic
attack [TIA]/stroke) within the 3 months before im-
aging. Baseline cardiovascular risk factors were
noted, including measurement of serum lipids and
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FIGURE 1 The VISION Study
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insufﬁcient mRNA extracted for quantitative PCR (n ¼ 2). ¶CT scans not completed (calcium scan, n ¼ 1; coronary angiogram, n ¼ 5; carotid
angiogram, n ¼ 2). ACS ¼ acute coronary syndrome; CT ¼ computed tomography; CVD ¼ cardiovascular disease; FDG ¼ ﬂuorodeox-
yglucose; PCR ¼ polymerase chain reaction; PET ¼ positron emission tomography; TIA ¼ transient ischemic attack; VISION ¼ Vascular
Inﬂammation imaging using Somatostatin receptor positron emissION tomography.
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1777older than 40 years of age and provided written,
informed consent. The study protocol approved by
the local research ethics committee (REC 14/EE/0019)
was in accordance with the Declaration of Helsinki.
PET-CT IMAGING. Patients underwent 68Ga-DOTATATE
PET-CT and [18F]FDG PET-CT imaging, using estab-
lished methods (13) for vascular PET imaging on a
Discovery 690 combined PET-CT system model (GE
Healthcare, Little Chalfont, United Kingdom;
extended Methods are detailed in the Online
Appendix). 68Ga-DOTATATE had an average radio-
chemical purity of 99% on quality control testing
performed by the manufacturer (Mallinckrodt, St.
Louis, Missouri). Patients fasted for 6 h prior to [18F]
FDG imaging; capillary blood glucose concentration
was conﬁrmed as <7.0 mmol/l in nondiabetic patients
prior to scanning. Patients with diabetes mellitus
were instructed to take their antidiabetic medications
as usual prior to [18F]FDG scanning but to hold
insulin within 4 h of the scan; if glucose level
was >11.0 mmol/l, the scan was rescheduled accord-
ing to our standard clinical practice. Insulin was not
administered to any patient prior to [18F]FDG PET
imaging. The mean injected dose of 68Ga-DOTATATE
was 147.8  31.6 MBq and 248.1  22.3 MBq for [18F]
FDG. Electrocardiography (ECG)-gated CT coronary
angiography plus calcium scanning and carotid angi-
ography were also performed.
IMAGE ANALYSIS. Static PET images were recon-
structed using 3-dimensional (3D) iterative time-of-
ﬂight ordered-subset expectation maximization with
point spread function modeling to reduce partial vol-
ume error. ECG-gated coronary PET images were
reconstructed in diastole (50% to 75% of the R–R in-
terval). PET-CT images were coregistered and
analyzed by experienced observers masked to the
clinical details, using OsiriX imaging software (version
7.0; Pixmeo, Bernex, Switzerland). CT angiography
was used as the anatomical reference standard; 2D
regions of interest were drawn on consecutive, fused
PET-CT slices to quantify the maximum arterial
radioactivity concentration, normalized by mean
blood pool activity in the superior vena cava
(maximum tissue-to-blood ratio [TBRmax]). Mean (m)
and most diseased segment (mds) TBRmax values were
measured for each coronary segment, carotid artery,
and thoracic aorta. Reproducibility of 68Ga-DOTATATE
TBR measurements were tested by 2 independent ob-
servers using 10% of the coronary and carotid scans
(n ¼ 4 for both) selected at random, with 1 week be-
tween intraobserver readings. Coronary artery PET
data were deemed uninterpretable if the maximum
myocardial standardized uptake value was >5.0.Coronary lesions were classiﬁed according to
established CT criteria for plaque composition (calci-
ﬁed, noncalciﬁed, or mixed plaque) and the presence
of high-risk morphological features (spotty calciﬁca-
tion [<3.0 mm], low attenuation [<30 HU], and pos-
itive remodeling [cross-sectional area >10% of a
reference segment]) (14).
“Culprit” lesions were deﬁned in patients with ACS
or TIA/stroke by the attending cardiologist or stroke
physician before PET imaging, with no involvement
of the VISION study team. Assignment of culprit ar-
tery status took clinical data into consideration (e.g.,
ECG, angiographic and echocardiographic ﬁndings,
site of any neurological deﬁcit at time of clinical
presentation, and carotid artery or brain imaging).
Arteries targeted for intervention (with percutaneous
coronary intervention or carotid endarterectomy
surgery) were presumed to be culprit arteries. In pa-
tients who were managed medically, if the culprit
lesion was uncertain, the relevant data were excluded
from this part of the analysis.
QUANTITATIVE POLYMERASE CHAIN REACTION.
The pattern of SSTR2 gene expression observed using
population-based RNA-sequenced data was conﬁrmed
in lipopolysaccharide-stimulated macrophages from
subjects in our imaging cohort by using quantitative
real-time polymerase chain reaction assay results and
compared to those of age- and sex-matched healthy
volunteers (n ¼ 3 for both). SSTR2 and CD68 mRNA
levels were measured in excised carotid plaques, and
compared with 68Ga-DOTATATE signals in PET images
obtained prior to surgery.
AUTORADIOGRAPHY AND HISTOLOGY. To conﬁrm
speciﬁc ligand binding in atherosclerotic plaques,
68Ga-DOTATATE autoradiography was performed in
carotid tissue sections adjacent to those used for
quantitative polymerase chain reaction. After the
radioactivity decayed, sections were stained with
antibodies for SST2, the panmacrophage marker
CD68, and Movat’s pentachrome stain for anatomic
characterization. Autoradiography and immuno-
staining were similarly tested in cultured macro-
phages. Colocalization of SST2 and CD68 staining in
macrophages within carotid plaque sections were
assessed by immunoﬂuorescence, with isotype and
concentration-matched immunoglobulin G (IgG) as
the negative control. The retention, storage, and use
of tissue sections and blood samples were compliant
with the UK Human Tissue Act of 2004.
STATISTICAL ANALYSIS. The primary outcome
was comparison of culprit versus nonculprit coronary
and carotid artery 68Ga-DOTATATE mTBRmax in
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ondary outcomes included comparisons of vascular
68Ga-DOTATATE mTBRmax values versus clinical CVD
risk factors, CT plaque morphology, [18F]FDG
mTBRmax, and SSTR2/CD68 gene expression levels in
excised carotid plaques. Primary and secondary
outcome data expressed as medians (interquartile
range [IQR]) were compared using Wilcoxon signed
rank test or Mann-Whitney U test, as appropriate,
with differences of medians derived for paired data.
For comparisons between more than 2 groups, the
Kruskal-Wallis test was used.
Based on 68Ga-DOTATATE TBR values from our
pilot work and previously published data (9), our
sample size (n ¼ 42) was chosen to detect differences
in mTBRmax of $1.13 between high- and low-risk ar-
teries, with 80% power and a 2-sided p value
of <0.05. Patients with stable and unstable CVD were
not formally matched as our primary comparison
used “within patient” data (culprit versus nonculprit
artery) rather than stable versus unstable patients.
We anticipated that if one-third of patients had TIA/
stroke, this would yield a comparable number of
explanted carotid specimens to similar PET validation
work performed by our group (15).
Spearman’s correlation and simple linear
regression were used to identify statistically sig-
niﬁcant clinical and biochemical predictors of
68Ga-DOTATATE mTBRmax that were then evaluated
together using multivariate analysis. In the regression
analysis, mean arterial values were used to mitigate
the problem of multiple observations, as each patient
contributed an equal number of arteries. Two-sided
p values of <0.05 were considered signiﬁcant.
Statistical analysis was performed using Prism
version 6.0 software (GraphPad Software, Redwood,
California) and Stata version 14.1 software (StataCorp,
Cary, North Carolina).
RESULTS
POPULATION-BASED VALIDATION OF SSTR2 GENE
EXPRESSION IN MACROPHAGES. Prior to clinical
PET imaging, we tested the target expression of
SSTR2 in blood-derived macrophages compared to
other relevant cell types by using data from a
large-scale population study. High levels of SSTR2
mRNA were detected exclusively in proinﬂammatory
M1 macrophages and no other macrophage pheno-
type. This pattern and degree of expression was
not seen for any other SST receptor subtype or cell
line (Figure 2). SSTR3 was expressed by CD4þ T
lymphocytes to a lesser extent, as is known to
occur (16).Very low levels of SSTR2 mRNA were detected in
unstimulated M0 macrophages and alternatively
activated M2 macrophages, but SSTR2 was not
expressed by any of the following cells: monocytes,
T or B lymphocytes, natural killer cells, platelets,
neutrophils, and endothelial cells. GLUT1 and GLUT3
were highly expressed by all cell types, demon-
strating that SSTR2 offers greater cell speciﬁcity
as an inﬂammation imaging target than glucose
metabolism.
CLINICAL STUDY. Baseline clinical data are summa-
rized in Table 1. The median time interval
between ACS and PET imaging was 35 days (IQR: 21 to
66 days) and 18 days (IQR: 11 to 25 days) for TIA/
stroke.
The reproducibility of 68Ga-DOTATATE TBRmax
measurements was excellent for both intraobserver
observations (coronary artery intraclass coefﬁcient
value [ICC]: 0.90; 95% conﬁdence interval [CI]: 0.85
to 0.94; carotid artery ICC: 0.96; 95% CI: 0.95 to 0.97)
and interobserver observations (coronary artery ICC:
0.96; 95% CI: 0.94 to 0.97; carotid artery ICC: 0.91;
95% CI: 0.88 to 0.94).
68GA-DOTATATE IDENTIFIES CULPRIT ACS LESIONS
IN CORONARY ARTERIES. Myocardial binding of
68Ga-DOTATATE was sufﬁciently low in all patients to
allow unimpeded coronary artery PET signal mea-
surement (Central Illustration, Online Figure 1). In
patients with ACS, culprit 68Ga-DOTATATE uptake
was consistently greater than the highest non-
culprit coronary segment within the same individual
(median difference mTBRmax: 0.69; IQR: 0.22 to 1.15;
p ¼ 0.008; median difference mdsTBRmax: 1.17; IQR:
0.45 to 1.70; p ¼ 0.02), regardless of whether the
lesion had been stented prior to imaging (culprit
stented mTBRmax: 2.91; IQR: 2.66 to 4.63 vs. stable
stented mTBRmax: 2.00; IQR: 1.51 to 2.70; p ¼ 0.006)
(Online Figure 2).
Using receiver operator characteristic (ROC) anal-
ysis, coronary 68Ga-DOTATATE mTBRmax values
>2.66 had 87.5% (95% CI: 47.4 to 99.7) sensitivity and
78.4% (95% CI: 72.4 to 83.6) speciﬁcity to detect a
culprit coronary segment (ROC area under the curve
[AUC]: 0.86; 95% CI: 0.78 to 0.93; p ¼ 0.0006).
68GA-DOTATATE IDENTIFIES HIGH-RISK STABLE
LESIONS IN CORONARY ARTERIES. Data from 6  2
coronary segments were analyzed from each patient.
Increased 68Ga-DOTATATE signals were often
observed in nonculprit (bystander) lesions in ACS
patients, particularly in low-attenuation plaques
deﬁned by CT (Figure 3). 68Ga-DOTATATE mTBRmax
values were higher in nonculprit coronary segments
in patients with both stable and unstable CVD, with
FIGURE 2 Target SSRT2 Expression in Proinﬂammatory Macrophages
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Heatmap of population-based RNA sequencing data (A) showing high SSTR2 expression in proinﬂammatory M1 macrophages (n¼ 4), very low levels of SSTR2 expression
in unstimulated M0 macrophages (n ¼ 4), and alternatively activated M2 macrophages (n ¼ 5). For comparison, a heatmap of GLUT1 and GLUT3 shows signiﬁcant gene
expression in all cell types (note, different scales for SSRT and GLUT genes; mean values are log2 fragments per kilobase of transcript for millionmapped reads [FPKMþ1]).
SSTR2 expression in LPS-stimulated macrophages from CVD patients versus age- and sex-matched healthy volunteers (n ¼ 3 for both) using quantitative PCR (B).
Photomicrograph shows green ﬂuorescent immunoreactive SST2 staining in macrophages (C), with blue nuclear DAPI-stained ([inset] concentration and isotype-
matched IgG negative control). Brightﬁeld photomicrograph shows brown immunoreactive SST2-stained culturedmacrophages, with nuclear counterstain (D). Phosphor
autoradiographic image shows total binding of 68Ga-DOTATATE (E) in clusters of cultured macrophages ([inset] parallel incubation with 68Ga-DOTATATE and cold
competing ligand showing very low levels of nonspeciﬁc binding). IgG ¼ immunoglobulin G; LPS ¼ lipopolysaccharide; other abbreviations as in Figure 1.
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1779either noncalciﬁed/mixed plaque morphology or with
high-risk CT features (spotty calciﬁcation, low atten-
uation, or positive remodeling) versus heavily calci-
ﬁed or normal arteries with no high-risk features
(p < 0.0001) (Figure 4).
Coronary 68Ga-DOTATATE mTBRmax >2.12 had
83.3% (95% CI: 67.2% to 93.6%) sensitivity and 71.7%
(95% CI: 64.6% to 78.0%) speciﬁcity (ROC AUC: 0.86;
95% CI: 0.80 to 0.92; p < 0.0001) to detect a segment
with at least 1 high-risk CT feature.68GA-DOTATATE IDENTIFIES CULPRIT TIA/STROKE
LESIONS IN CAROTID ARTERIES. In patients with TIA
or stroke, increased 68Ga-DOTATATE inﬂammatory
signals reliably differentiated between culprit carotid
plaques and contralateral nonculprit carotid arteries
(median difference mTBRmax: 0.13; IQR: 0.07 to 0.32;
p ¼ 0.003; median difference mdsTBRmax: 0.34;
IQR: 0.01 to 0.53; p ¼ 0.005) (Figure 5). Contralat-
eral carotid 68Ga-DOTATATE mdsTBRmax in patients
with TIA/stroke was also greater than in diseased
TABLE 1 Baseline Clinical Factors
Stable CVD
(n ¼ 18)
Unstable CVD*
(n ¼ 24)
All
(n ¼ 42)
Age, yrs 67  10 71  7 69  9
Male 14 (78) 20 (83) 34 (81)
Body mass index, kg/m2 29  5 27  4 28  5
Heart rate, beats/min 57  9 58  6 57  8
Systolic blood pressure, mm Hg 141  22 144  24 143  21
Diastolic blood pressure, mm Hg 74  9 76  10 75  9
Occurrences of previous cardiovascular history
Angina 8 (44) 4 (17) 12 (29)
Myocardial infarction 3 (17) 9 (38) 12 (29)
Coronary stenting 5 (28) 3 (13) 8 (19)
Coronary artery bypass surgery 1 (6) 3 (13) 4 (10)
Transient ischemia attack or stroke 4 (22) 3 (13) 7 (17)
Carotid endarterectomy surgery 2 (11) 0 (0) 2 (5)
Occurrences of cardiovascular risk factors
Hypertension 9 (50) 16 (67) 25 (60)
Hypercholesterolemia 17 (94) 17 (71) 34 (81)
Noninsulin dependent diabetes 2 (11) 6 (25) 8 (19)
Smoking habit (ex or current) 10 (56) 18 (75) 28 (67)
Family history of coronary heart disease† 7 (39) 12 (50) 19 (45)
Occurrences of cardiovascular medications
Aspirin 15 (83) 15 (63) 30 (71)
Clopidogrel 6 (33) 21 (88) 27 (64)
Statin 16 (89) 22 (92) 38 (91)
b-Adrenergic receptor blocker 11 (61) 14 (58) 25 (60)
Angiotensin converting enzyme
inhibitor/receptor blocker
8 (44) 17 (71) 25 (60)
Calcium-channel blocker 3 (17) 9 (38) 12 (29)
Other antihypertensive 3 (17) 4 (17) 7 (17)
Oral nitrates 4 (22) 3 (13) 7 (17)
Random lipid proﬁle
Total cholesterol, mmol/l 4.0  1.1 3.6  0.9 3.8  0.8
HDL cholesterol, mmol/l 1.1  0.2 1.1  0.3 1.1  0.2
LDL cholesterol, mmol/l 2.1  0.6 1.9  0.7 2.0  0.7
Triglycerides, mmol/l 1.8  0.9 1.3  0.5 1.5  0.7
HDL cholesterol, mmol/l 3.8  1.0 3.4  0.7 3.6  0.9
Median high-sensitivity CRP, mg/l 2.5 (0.8–3.7) 2.1 (0.7–5.8) 2.4 (0.7–4.6)
Median peak serum troponin-I
concentration, ng/l‡
– 573 (59.5–3,957) –
Median %10-year Framingham risk score 9 (8–21) 18 (11–26) 16 (8–26)
Median coronary artery calcium
score, Agatston units
177 (96–680) 756 (255–1,419) 433 (120–1,314)
Values are mean  SD, n (%), or mean (interquartile range). *Unstable CVD ¼ ACS or TIA/stroke within the
previous 3 months. †<65 years of age. ‡ACS patients.
ACS ¼ acute coronary syndrome; CRP ¼ C-reactive protein; CVD ¼ cardiovascular disease; HDL ¼ high-density
lipoprotein; LDL ¼ low-density lipoprotein; TIA ¼ transient ischemic attack.
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1780(p ¼ 0.01) or normal (p ¼ 0.0001) carotids from
patients with stable CVD (i.e., those without TIA/
stroke or ACS). Nonculprit carotid 68Ga-DOTATATE
mTBRmax was also higher in patients with unstable
CVD (either TIA/stroke or ACS) versus stable CVD
(p ¼ 0.02).
AORTIC 68GA-DOTATATE SIGNALS ARE RELATED TO
CORONARY 68GA-DOTATATE SIGNALS. 68Ga-DOTATATEmTBRmax values in the coronary arteries and
neighboring aorta showed a moderate correlation
(r ¼ 0.43; 95% CI: 0.11 to 0.66; p ¼ 0.008). Aortic 68Ga-
DOTATATE mTBRmax was negatively correlated with
coronary calcium scores in patients with a total score
of <400 (r ¼ 0.66; 95% CI: 0.87 to 0.26; p ¼ 0.003).
VASCULAR 68GA-DOTATATE SIGNALS ARE RELATED
TO CLINICAL CVD RISK FACTORS. Relationships
between vascular 68Ga-DOTATATE signals and clin-
ical CVD risk factors were evaluated to explore
possible mechanistic links between 68Ga-DOTATATE
and underlying disease pathology. Age (r ¼ 0.44; 95%
CI: 0.20 to 0.62; p ¼ 0.0004), total cholesterol
(r ¼ 0.51; 95% CI: 0.30 to 0.68]; p < 0.0001), and
Framingham risk score (r ¼ 0.53; 95% CI: 0.32 to 0.69;
p <0.0001) showed signiﬁcant correlations with ca-
rotid 68Ga-DOTATATE mTBRmax (Figure 6). Carotid
68Ga-DOTATATE mTBRmax also differed signiﬁcantly
across patients grouped according to Framingham
risk score (p < 0.0001). Body mass index (BMI) was
positively correlated with aortic 68Ga-DOTATATE
mTBRmax (r ¼ 0.38; 95% CI: 0.06 to 0.64; p ¼ 0.017).
When age, total cholesterol, and BMI were evalu-
ated with other relevant clinical factors using multi-
variate linear regression, they remained signiﬁcant
predictors of 68Ga-DOTATATE mTBRmax (Online
Table 1).
Carotid 68Ga-DOTATATE TBRmax values also varied
signiﬁcantly in patients without TIA/stroke who
were taking statins, with lower values seen in pa-
tients taking high-intensity statins compared to
those taking moderate or low dosages (p ¼ 0.004)
(Figure 7).
In the 1.6  0.2 years following PET imaging, 2 pa-
tients attended the emergency department with
nonanginal chest pain, and there were 2 out-of-
hospital deaths; our study was not powered to assess
the ability of PET imaging to predict clinical events.
COMPARISON OF 68GA-DOTATATE VERSUS [18F]
FDG-DEFINED INFLAMMATION. The time interval
between 68Ga-DOTATATE and [18F]FDG imaging was
a median of 2 days (IQR: 1 to 7 days). Coronary, ca-
rotid, and aortic 68Ga-DOTATATE and [18F]FDG
mTBRmax values were strongly correlated with each
other (r ¼ 0.73; 95% CI: 0.64 to 0.81; p < 0.0001),
although coronary artery [18F]FDG data were unin-
terpretable in 27 (64%) patients because of high
myocardial spillover. Of 2 ACS patients with inter-
pretable coronary [18F]FDG data, culprit mTBRmax
values were numerically higher than the highest
nonculprit segment in 1 patient.
[18F]FDG mTBRmax but not mdsTBRmax differenti-
ated culprit from contralateral carotids (median
CENTRAL ILLUSTRATION Comparison Between 68Ga-DOTATATE and [18F]FDG Coronary PET Inﬂammation Imaging
Tarkin, J.M. et al. J Am Coll Cardiol. 2017;69(14):1774–91.
Images from a 57-year old man with acute coronary syndrome who presented with deep anterolateral T-wave inversion (arrow) on electrocardiogram (A) and serum
troponin-I concentration elevated at 4,650 ng/l (NR: <17 ng/l). Culprit left anterior descending artery stenosis (dashed oval) was identiﬁed by X-ray angiography (B).
After the patient underwent percutaneous coronary stenting (C), residual coronary plaque (*inset) with high-risk morphology (low attenuation and spotty calciﬁcation)
is evident on CT angiography (D, E). Use of 68Ga-DOTATATE PET (F, H, I) clearly detected intense inﬂammation in this high-risk atherosclerotic plaque/distal portion
of the stented culprit lesion (arrow) and recently infarcted myocardium (*). In contrast, using [18F]FDG PET (G, J), myocardial spillover completely obscures
the coronary arteries. CT ¼ computed tomography; [18F]FDG ¼ ﬂuorine-18-labeled ﬂuorodeoxyglucose; 68Ga-DOTATATE ¼ gallium-68-labeled DOTATATE;
PET ¼ positron emission tomography.
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1781difference: 0.12; IQR: 0.00 to 0.23; p ¼ 0.008). Com-
parisons between coronary [18F]FDG mTBRmax values
and CT morphology are shown in Figure 4 and clinical
risk factors in Figure 6. Coronary 68F-FDG mTBRmax of
>2.05 had 53.3% (95% CI: 26.6% to 78.7%) sensitivity
and 92.4% (95% CI: 83.2% to 97.5%) speciﬁcity (ROC
AUC: 0.76; 95% CI: 0.62 to 0.91; p ¼ 0.002) for high-risk CT features. 68Ga-DOTATATE demonstrated
higher TBR values and superior ability to discriminate
high-risk versus low-risk coronary atherosclerotic le-
sions than [18F]FDG.
TARGET VALIDATION IN MACROPHAGES FROM CVD
PATIENTS. In CVD patients, macrophage SSTR2
FIGURE 3 Coronary PET Inﬂammation Imaging: ACS Culprit Versus Bystander Lesions
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X-ray angiography images from a 59-year old man with ACS, showing a culprit ﬁrst obtuse marginal lesion ([A] hatched oval) and nonculprit (bystander) right coronary
artery disease ([E] circle). Identiﬁcation of a culprit artery was aided by electrocardiographic ﬁndings of lateral T-wave inversion. Corresponding CT angiography
images (B, F) show stented culprit lesion (*) and native bystander lesion with high-risk plaque morphology ([inset] low attenuation, cross-section of artery with outer
wall boundary marked by dotted outline). In both lesions, intense inﬂammation (arrows) detected by 68Ga-DOTATATE PET (C, G) is reproduced by [18F]FDG PET (D,
H). Graphs of culprit versus highest nonculprit coronary 68Ga-DOTATATE TBRmax values in patients (n ¼ 8) with ACS and stented culprit ACS lesions (n ¼ 6) versus
stable stented (n ¼ 18) lesions (I). ROC analysis demonstrates good diagnostic accuracy of 68Ga-DOTATATE for culprit coronary lesions (J). Note stable stented lesions
are coronary stents that were inserted >3 months prior to PET imaging in all but 1 patient. AUC ¼ area under curve; mTBRmax ¼ mean of maximum tissue-to-blood
ratios; ROC ¼ receiver operating characteristic; other abbreviations as in Figures 1 and 2.
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1782mRNA was increased a median 91-fold (IQR: 56 to
104) above baseline versus 13-fold (IQR: 4.0 to
25) in age- and sex-matched healthy volunteers
(p ¼ 0.01), after stimulation with lipopolysaccharide.Presence of SST2 receptors was conﬁrmed by
immunostaining and speciﬁc binding of 68Ga-DOTA-
TATE to SST2 in cultured macrophages shown by
autoradiography.
FIGURE 4 Coronary PET Inﬂammation Imaging: High-Risk CT Features
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(A) X-ray and (D) CT coronary angiograms of a 67-year-old man with stable angina, showing minor LCx atheroma (hatched oval) with spotty
calciﬁcation ([inset] *calcium scan) and calciﬁed plaque in the LAD artery. Although 68Ga-DOTATATE PET (B, E) allows unimpeded inter-
pretation of inﬂammation in the LCx lesion (B, arrow), and lack of signal in the LAD, coronary [18F]FDG imaging is obscured by patchy
myocardial tracer uptake (C). Graphs compare 68Ga-DOTATATE (F) with [18F]FDG (G) coronary TBRmax values by CT plaque morphology in
coronary segments (68Ga-DOTATATE: NCP or MP, n ¼ 86; normal, n ¼ 45; spotty calcium, n ¼ 30; large calcium, n ¼ 72; LA or PR, n ¼ 11; no
high-risk CT, n ¼ 186; [18F]FDG: NCP or MP, n ¼ 43; normal, n ¼ 13; spotty calcium, n ¼ 15; large calcium n ¼ 14; LA or PR, n ¼ 4; no high-risk
CT, n ¼ 66), and ROC analysis demonstrating good diagnostic accuracy for high-risk coronary lesions. LA ¼ low attenuation; LAD ¼ left
anterior descending; LCx ¼ left circumﬂex; NCP ¼ noncalciﬁed plaque; MP ¼mixed plaque; PR ¼ positive remodeling; other abbreviations in
Figures 1 to 3.
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1783AUTORADIOGRAPHIC AND HISTOLOGICAL TARGET
VALIDATION IN CAROTID PLAQUES. Following
PET-CT imaging, 8 patients underwent carotid end-
arterectomy. The PET scan-to-surgery time interval
was a median of 9 (IQR: 3 to 35) days. Ex vivo
68Ga-DOTATATE carotid autoradiography showedhigh levels of speciﬁc ligand binding to SST2 re-
ceptors in all specimens (n ¼ 8). A small degree
of nonspeciﬁc binding was seen in relation to
freshly cut calcium and as a result of edge artifact,
which occurs when tissue edges curl causing the
ligand to remain trapped during the experiment.
FIGURE 5 Carotid PET Inﬂammation Imaging: TIA/Stroke
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Views from a 66-year-old man ([top] axial plane) and a 70-year-old man ([bottom] sagittal plane), both of whom had TIAs resulting from right
internal carotid artery lesions, shown on CT (A [hatched circle], D [*]), with intense culprit plaque inﬂammation (hatched circles/arrows)
detected by 68Ga-DOTATATE (B, E) and reproduced by [18F]FDG (C, F). Graphs compare culprit versus nonculprit 68Ga-DOTATATE (G) and [18F]
FDG (H) TBRmax values (68Ga-DOTATATE: culprit n¼ 14; contralateral n¼ 14; nonculprit [unstable CVD] n¼ 31; nonculprit [stable CVD] n¼ 24;
contralateral [TIA/stroke] n¼ 14; diseased stable CVD n¼ 19; [18F]FDG: culprit n¼ 13; contralateral n¼ 13; nonculprit [unstable CVD] n¼ 31;
nonculprit [stable CVD] n ¼ 24; contralateral [TIA/stroke] n ¼ 13; diseased [stable CVD] n ¼ 19). TIA ¼ transient ischemic attack; other ab-
breviations as in Figures 1 to 3.
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178468Ga-DOTATATE binding within carotid plaques
occurred mainly in the necrotic cores and shoulder
regions, where there was strong colocalization
of CD68 and SST2 staining (Figure 8, Online Figure 3).Neither 68Ga-DOTATATE binding nor SST2
staining was observed within thick ﬁbrous cap re-
gions consisting mainly of vascular smooth muscle
cells.
FIGURE 6 Vascular Inﬂammation Versus Clinical Risk Factors
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Graphs show correlations of vascular inﬂammation detected by 68Ga-DOTATATE (A to C) and [18F]FDG (D) versus clinical cardiovascular
disease risk factors. (Carotid arteries n ¼ 62; aortas, n ¼ 38; note data from patients not taking statins [n ¼ 4] were excluded to control for
this variable). Abbreviations as in Figure 1.
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1785CAROTID SSTR2/CD68 mRNA VERSUS 68GA-DOTATATE
ACTIVITY. SSTR2 and CD68 mRNA levels were highly
correlated within carotid plaque (r ¼ 0.93; 95% CI:
0.49 to 0.99; p ¼ 0.007) (Figure 9). Carotid SSTR2 and
CD68 mRNA levels also showed strong correlation
with in vivo 68Ga-DOTATATE TBRmax values
measured at the corresponding level in clinical
PET images, orientated at the bifurcation (SSTR2
r ¼ 0.89; 95% CI: 0.28 to 0.99; p ¼ 0.02; CD68 r ¼ 0.84;
95% CI: 0.09 to 0.98; p ¼ 0.04). Moreover, immuno-
ﬂuorescence demonstrated high cell speciﬁcity of
colocalized of SST2 and CD68 staining in carotid pla-
que macrophages. These data provided both histo-
logical and molecular validation of 68Ga-DOTATATE
as a speciﬁc marker of atherosclerotic inﬂammation.
DISCUSSION
There have been previous reports of 68Ga-DOTATATE
imaging in atherosclerosis, but they have been pre-
clinical or retrospective studies, with the exceptionof 1 report limited to the carotid arteries. We provide
the ﬁrst deﬁnitive prospective validation of 68Ga-
DOTATATE imaging as a marker of atherosclerotic
inﬂammation.
WHICH CELLS EXPRESS SSTR2 IN ATHEROSCLEROSIS? We
conﬁrmed that high target SSTR2 gene expression
occurs exclusively among activated proinﬂammatory
M1 macrophages in atherosclerosis and demonstrated
the presence of SST2 receptors in macrophages from
patients with CVD. As a glucose analog, [18F]FDG
lacks cell speciﬁcity, but there is some evidence that
[18F]FDG accumulates more in M1 macrophages than
in other macrophage subtypes because of differing
glycolytic activity between these cells (17).
BINDING OF 68GA-DOTATATEWITHIN ATHEROSCLEROTIC
PLAQUES. We observed speciﬁc 68Ga-DOTATATE
ligand binding to SST2 receptors within CD68þ
macrophage-rich carotid plaque regions and strong
correlations between carotid SSTR2 mRNA and
in vivo 68Ga-DOTATATE activity. Although low levels
FIGURE 7 68Ga-DOTATATE Versus [18F]FDG-Deﬁned Inﬂammation and Other Clinical Factors
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Graphs show (A) the strong correlations among coronary, carotid, and aortic 68Ga-DOTATATE mTBRmax versus [18F]FDG mTBRmax (n ¼ 123
mean arterial values per tracer); (B) carotid 68Ga-DOTATATE mTBRmax grouped by FRS (<8%, n ¼ 16; 8% to 16%, n ¼ 14; >16%, n ¼ 32);
(C) negative correlation of coronary aortic mTBRmax versus calcium score in patients with CAC <400 (n ¼ 19); and (D) carotid 68Ga-DOTATATE
TBRmax ROI values in non TIA/stroke patients grouped by statin dosages (n ¼ 20 patients [14 ROIs per artery]; low-dose n ¼ 4; moderate
dose, n ¼ 9; high-dose, n ¼ 7). Log transformed CAC values used to account for the non-normal distribution in the general population.
Median difference between low-dose vs. high-dose: 0.13; (95% CI: 0.17 to 0.016); p ¼ 0.02; %D 8.65. Low dose: simvastatin,
20 mg or lower; high-dose: atorvastatin, 80 mg or equivalent; moderate dose: all other dosages. CAC ¼ coronary artery calcium score;
FRS ¼ %10-year Framingham risk score; ROI ¼ region of interest; TIA ¼ transient ischemic attack.
Tarkin et al. J A C C V O L . 6 9 , N O . 1 4 , 2 0 1 7
Vascular Inﬂammation Imaging Using 68Ga-DOTATATE PET A P R I L 1 1 , 2 0 1 7 : 1 7 7 4 – 9 1
1786of SST2 expression have been previously reported in
vascular smooth muscle cells, we did not observe
68Ga-DOTATATE binding nor SST2 staining within the
thick ﬁbrous cap regions where these cells are abun-
dant, suggesting that the synthetic atherosclerotic
vascular smooth muscle cell phenotype is unlikely to
express SST2 to a degree that would be detectable by
clinical imaging. These laboratory-based ﬁndings
provide robust histological and molecular validation
of 68Ga-DOTATATE as a speciﬁc marker of athero-
sclerotic inﬂammation.
CULPRIT AND HIGH-RISK PLAQUE INFLAMMATION.
In clinical imaging, we found that 68Ga-DOTATATE
PET correctly identiﬁed culprit coronary and carotidarteries in individuals with ACS or TIA/stroke. The
median difference between culprit and nonculprit
carotid arteries was less pronounced than in coronary
arteries, but these 2 regions are not necessarily
directly comparable because of the high prevalence
of asymptomatic contralateral carotid disease,
differing imaging time points affecting tracer ki-
netics, and local factors determining tracer delivery
and clearance. 68Ga-DOTATATE demonstrated reli-
able diagnostic accuracy to detect stable yet inﬂamed
coronary lesions with high-risk CT morphological
features.
SYSTEMIC INFLAMMATION. The ability of 68Ga-
DOTATATE to detect generalized vascular
FIGURE 8 68Ga-DOTATATE Ligand Binding to Macrophage SST2 in Carotid Plaque
In vivo CT angiography views of culprit carotid artery (hatched oval ¼ internal carotid artery) in axial (A) and sagittal (E) views, with corresponding fused
68Ga-DOTATATE PET-CT (B). Ex vivo views of macrographic images of the explanted carotid specimen (I, hatched line signiﬁes location of carotid section); phosphor
autoradiographic image shows the total binding of 68Ga-DOTATATE to SST2 receptors in macrophages within a transverse carotid section (C) corresponding to the level
shown in clinical images. Adjacent section was incubated with 68Ga-DOTATATE and cold competing ligand (D) showing very low levels of nonspeciﬁc binding.
Brightﬁeld photomicrographs show brown immunoreactive SST2 staining (G, J, M) of macrophages identiﬁed with the panmacrophage marker CD68 (H, K, N),
colocalized SST2 (brown), and CD68 (blue) staining in the same section (L); Movat’s pentachrome stain (F).
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FIGURE 9 Carotid SSTR2/CD68 mRNA Versus In Vivo 68Ga-DOTATATE Activity
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Graphs show correlations of SSTR2 versus CD68 mRNA within ex vivo carotid plaques measured by quantitative PCR (A); SSTR2 (B) and CD68
(C) mRNA versus corresponding in vivo 68Ga-DOTATATE TBRmax values measured from clinical images (n ¼ 6). Representative photomi-
crograph shows red SST2 and green CD68 ﬂuorescent immunoreactive staining of macrophages within carotid plaque (D), with blue nuclear
DAPI staining. Note presence of both double positive (þ) and double negative () staining indicating high cell speciﬁcity (E).
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1788inﬂammation was shown by the close relationship
between PET signals in neighboring coronary and
aortic vasculature and increased inﬂammatory signals
arising from nonculprit carotids in patients with un-
stable CVD. Both of these features have been previ-
ously demonstrated using [18F]FDG (2). Moreover,
signiﬁcant correlations were observed between clin-
ical CVD risk factors and generalized vascular 68Ga-
DOTATATE inﬂammatory signals, which were overall
lower in patients receiving high-intensity statins and
with increasing coronary calcium scores up to 400.
The inverse relationship between statin dosages and
signal intensity provide anecdotal evidence that68Ga-DOTATATE PET may provide a useful imaging
platform for monitoring the anti-inﬂammatory effects
of atherosclerosis drugs.
68GA-DOTATATE OUTPERFORMS [18F]FDG. Although
68Ga-DOTATATE signals were strongly correlated
with [18F]FDG-deﬁned inﬂammation in multiple
vascular territories, disparity between these 2 tracers
reﬂects the fact that 68Ga-DOTATATE is a speciﬁc
macrophage marker in atherosclerosis, whereas [18F]
FDG provides a nonspeciﬁc measurement of glucose
metabolism within plaque cells. Superiority of
68Ga-DOTATATE compared with [18F]FDG was
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1789shown by better power to discriminate high-risk
versus low-risk coronary atherosclerotic lesions,
higher signal-to-blood ratios, and consistently lower
myocardial activity, affording clear coronary signal
interpretation.
[18F]FDG imaging is notoriously unreliable in coro-
naries; in contrast, myocardial 68Ga-DOTATATE bind-
ing was sufﬁciently low to allow coronary artery
inﬂammation imaging in all patients. 68Ga-DOTATATE
inﬂammatory signals differentiated culprit from
contralateral carotids, using both “mean of the whole
artery” and “most-diseased segment” methods, but
[18F]FDG only detected a difference in mean carotid
uptake, hinting that 68Ga-DOTATATEmay offer amore
focal approach. 68Ga-DOTATATE signals also appeared
more discretely localized than [18F]FDG signals in
clinical images (Figures 3 and 5). Given the higher cost
of 68Ga-DOTATATE than [18F]FDG, its use for non-
coronary vascular imaging may not be justiﬁed,
although in the context of research, increased macro-
phage speciﬁcity of 68Ga-DOTATATE potentially holds
signiﬁcant advantage for detection of subtle changes
in vascular biology that may not be as clearly appreci-
ated using a blunter imaging tool such as [18F]FDG.
A small number of previous studies have investi-
gated SST2 PET imaging in CVD. Two studies
demonstrated autoradiographic 68Ga-DOTATATE
binding within macrophage-rich aortic atheroscle-
rotic plaques in mice (6,7). Five retrospective ana-
lyses of PET scans from patients who underwent
imaging for oncological indications reported signiﬁ-
cant statistical relationships between vascular SST2
signals and clinical CVD factors, including older age,
male sex, hypercholesterolemia, presence of calciﬁed
coronary plaque, prior CVD events, and Framingham
risk score calculated using BMI (8–10,18,19). In 1
study, a strong correlation was observed between
68Ga-DOTATATE and [18F]FDG vascular TBR values,
although signals from the 2 tracers did not colocalize
at the sites of highest tracer uptake (9). In another
study of 11 patients who underwent 3 serial
68Ga-DOTATATE scans following peptide receptor
radionuclide therapy with lutetium-177-labeled
DOTATATE, good interscan reproducibility of 68Ga-
DOTATATE TBR measurements prior to radionuclide
therapy was observed, as well as signiﬁcant signal
reduction 1 month after, which was most pronounced
in relation to noncalciﬁed plaques (10). These studies,
although retrospective and without CT angiography
or ECG-gating, are consistent with our ﬁndings.
Our ﬁnding that SST2 PET can differentiate culprit
from contralateral carotid arteries is supported by
another study of 64Cu-DOTATATE PET cardiac mag-
netic resonance in 10 patients with carotid TIA/stroke(20). However, in that study, correlation between
carotid copper-64-labeled DOTATATE signals and
gene expression of the monocyte/macrophage marker
CD163 was observed using a multivariate regression
model, leading the authors to conclude that this
tracer reports on alternatively activated M2 macro-
phages. As hemoglobin-haptoglobin scavenging by
CD163 in the setting of intraplaque hemorrhage di-
rects monocyte differentiation toward an atheropro-
tective M2 phenotype (21), the ﬁnding of increased
CD163 mRNA within advanced ruptured plaques is
unsurprising. However, there is no current evidence
to indicate that signiﬁcant SSTR2 expression occurs in
M2 macrophages. Our ﬁndings agree with those of
previous work indicating that 68Ga-DOTATATE sig-
nals in atherosclerosis occur because of intracellular
tracer accumulation following cell surface binding
and receptor internalization among dense clusters of
classically activated M1 macrophages (22).
Next steps involve testing in a larger, longitudinal
study with clinical outcomes, similar to the ongoing
BioImage (NCT00738725) and PESA (Progression of
Early Subclinical Atherosclerosis; NCT01410318) [18F]
FDG studies.
STUDY LIMITATIONS. Limitations of our study
include inherent technical challenges of vascular PET
imaging, namely low spatial resolution (w5 mm) and
image artifacts created by cardiorespiratory motion
that are confounded by the high positron energy of
68Ga (Emax: 1.9 MeV; average positron range: 2.4 mm).
To overcome these difﬁculties, we used CT angiog-
raphy for precise anatomical PET signal localization
(spatial resolution: 0.5 to 0.6 mm), ECG-gated PET
reconstruction to reduce the impact of motion, and
iterative time-of-ﬂight reconstruction with point
spread function modeling to provide resolution
recovery and reduce partial volume error. Coronary
signal-to-noise ratio could potentially be improved
further by motion correction methods in active
development (23).
We did not attempt myocardial suppression of [18F]
FDG using dietary manipulation or prolonged fasting,
because in our experience, these methods are inef-
fective in w50% of cases (3) and are inconvenient for
patients. Nevertheless, others have reported success
using these methods.
Most of the ACS patients underwent stenting prior
to PET imaging and persistence of procedure-related
inﬂammation could have, in theory, augmented in-
ﬂammatory signals detected in culprit coronary le-
sions. Clinical identiﬁcation of culprit arteries can be
challenging, particularly in the coronary arteries;
although intravascular imaging can be used to
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: 68Ga-
DOTATATE binds to somatostatin receptor-2 (SST2) in
activated inﬂammatory macrophages, and the tissue-
to-blood ratios of 68Ga-DOTATATE distinguishes
culprit from nonculprit coronary and carotid arteries in
patients with ACS, stroke, or TIA. Although [18F]FDG
also differentiates these types of arterial lesions,
myocardial spillover renders coronary [18F]FDG PET
scans uninterpretable in a high proportion of patients.
TRANSLATIONAL OUTLOOK: Future research
should explore the utility of 68Ga-DOTATATE PET
imaging of inﬂammation to classify patients for more
aggressive therapeutic intervention and explore po-
tential application to other inﬂammatory cardiovas-
cular diseases.
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1790conﬁrm plaque rupture, this investigation was not
performed in any of the patients in this study. Last,
although the novel ﬁnding of increased SSTR2
expression in LPS-stimulated macrophages from
patients with CVD versus healthy volunteers is
intriguing, further testing in a larger patient cohort is
needed.
CONCLUSIONS
We provide gene-, cell-, plaque-, and patient-level
data demonstrating that SST2 PET imaging using
68Ga-DOTATATE provides a quantiﬁable, cell-
speciﬁc marker of atherosclerotic inﬂammation that
outperforms [18F]FDG in the coronary arteries.
Further work is needed to conﬁrm these ﬁndings in
a larger patient population and to compare imaging
with clinical outcomes. 68Ga-DOTATATE PET offers
measurement of both generalized atherosclerotic
disease activity and detailed information about local
plaque functional phenotype to complement multi-
modal assessments of anatomic, morphologic, and
hemodynamic disease severity. This approach, in
selected patient populations, has the potential to
improve CVD risk prediction, allowing personalized
tailoring of therapies aimed to improve clinical
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